Cue Biopharma prices $20M public offering; $13.1M cash; runway into Q2 2026

Cue Biopharma, Inc.

Pricing of 13.53M common shares + warrants at $0.79/unit; $20M gross proceeds.
Net proceeds estimated at $18M; closing expected April 16, 2025.
Preliminary cash and cash equivalents of $13.1M as of March 31, 2025 (unaudited).
Including $12M upfront from Boehringer Ingelheim deal, cash runway extended into Q2 2026.
Offering includes pre-funded warrants for 11.47M shares at $0.001 exercise price.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.